tiprankstipranks
Inhibikase Therapeutics (IKT)
NASDAQ:IKT
Holding IKT?
Track your performance easily

Inhibikase Therapeutics (IKT) Income Statement

163 Followers

Inhibikase Therapeutics Income Statement

Last quarter (Q3 2024), Inhibikase Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Inhibikase Therapeutics's net income was $-5.78M. See Inhibikase Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-$ 260.50K$ 123.44K$ 3.10M$ 0.00$ 1.12M
Cost of Revenue
------
Gross Profit
-$ 260.50K$ 123.44K$ 3.10M--
Operating Expense
$ 20.51M$ 20.09M$ 18.13M$ 17.87M$ 2.82M$ 6.82M
Operating Income
$ -20.43M$ -20.09M$ -18.13M$ -14.77M$ -2.82M$ -5.70M
Net Non Operating Interest Income Expense
$ 446.74K$ 1.06M$ 74.45K$ -19.92K$ -29.40K$ -24.84K
Other Income Expense
$ -2.45K$ 103.84K$ -104.72K$ 688.78K--
Pretax Income
$ -19.98M$ -19.03M$ -18.05M$ -14.79M$ -2.85M$ -5.72M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -19.98M$ -19.03M$ -18.05M$ -14.79M$ -2.85M$ -5.72M
Basic EPS
$ -2.90$ -3.57$ -4.28$ -0.81$ -0.35$ -0.53
Diluted EPS
$ -2.90$ -3.57$ -4.28$ -0.81$ -0.35$ -0.53
Basic Average Shares
$ 28.10M$ 5.33M$ 4.22M$ 18.21M$ 8.21M$ 10.03M
Diluted Average Shares
$ 28.10M$ 5.33M$ 4.22M$ 18.21M$ 8.21M$ 10.03M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 20.51M$ 20.09M$ 18.13M$ 17.87M$ 2.82M$ 6.82M
Net Income From Continuing And Discontinued Operation
$ -19.98M$ -19.03M$ -18.05M$ -14.79M$ -2.85M$ -5.72M
Normalized Income
$ -10.63M---$ -2.85M$ -5.72M
Interest Expense
----$ 29.40K$ 24.84K
EBIT
$ -20.43M$ -20.09M$ -18.13M$ -14.77M$ -2.82M$ -5.70M
EBITDA
$ -20.41M$ -19.91M$ -18.12M$ -14.77M$ -2.82M$ -5.70M
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis